T HE ADOPTION OF EVIDENCE-
based therapies for the treatment of cardiovascular diseases has been extensively studied in the clinical trials setting, registries, and claims data. [1] [2] [3] [4] [5] [6] The rapidity with which medications are accepted into clinical practice following the publication of positive trials data varies. For example, the uptake of some heart failure medications, such as angiotensinconverting enzyme (ACE) inhibitors was slow [7] [8] [9] [10] [11] despite the publication of landmark studies 12, 13 and incorporation of the therapy into clinical practice guidelines. 14 Conversely, the use of spironolactone increased significantly after release of the Randomized Aldactone Evaluation Study (RALES) trial data, 15 with unexpected consequences. 4, 16 The factors that lead to a decrease in the use of a drug or other intervention have not been as extensively studied. The observation has been made that drugs may fall out of favor as other therapeutic options evolve. 5, [17] [18] [19] However, less is known about the impact on practice of published studies suggesting adverse effects or possible safety concerns following regulatory approval. A few anecdotal examples do exist, however. In the 1970s, the use of lipid-lowering drugs such as clofibrate decreased in the years following the publication of a series of adverse articles emanating from the Coronary Drug Project. 20 Prescriptions for ␣-adrenergic blockers fell, albeit modestly, after data suggested a possible adverse effect in hypertension relative to thiazide diuretics. 21 The publication of an outcomes analysis from the Women's Health Initiative 22 had an impact on prescriptions written for hormone replacement therapy in women aged 55 years and older. 23 The data, derived from the records of a pharmacy benefits management company, suggested rapid decreases in both new and repeat prescriptions. However, 2 prior clinical trials that failed to demonstrate prevention of coronary heart or cerebrovascular events with hormone replacement therapy did not change prescribing practice.
In the area of acutely decompensated heart failure, the approval of nesiritide in August 2001 for the relief of dyspnea and acute lowering of pulmonary capillary wedge pressure on the basis of a series of trials [24] [25] [26] provided a potential new avenue for pharmacologic treatment. A survival indication was not included for this or any other drug in use for acutely decompensated heart failure. However, 2 publications in prominent medical journals in the spring of 2005 reported associations between nesiritide use and adverse effects, specifically, worsening renal function 27 and death. 28 Subsequently, a commentary-type publication appeared in which a prominent author called for the withdrawal of nesiritide from the market. 29 We hypothesized that there would be a rapid decrease in the use of nesiritide. Furthermore, we anticipated an increase in alternative therapies for advanced heart failure with a focus on therapies (dobutamine and milrinone) that have had a well-known potential association with increased mortality. [30] [31] [32] [33] [34] [35] [36] This trade-off raised the possibility that the publication and subsequent dissemination of the nesiritide data had an unexpected impact on practice and patient care. Because no other drugs had been approved for the treatment of acutely decompensated heart failure since the launch of nesiritide in September 2001 (BOX), we also were able to compare recent trends in the use of intravenous vasoactive therapy with practice before the medication's approval.
METHODS
We used data from Premier's Perspective Comparative Database, a large US hospital clinical and economic database developed for quality and utilization benchmarking. This database includes patient-level data on each admission from approximately 800 acute care hospitals across the United States, providing nationally representative information on nearly 5 million annual hospital discharges at both rural and urban hospitals. All data are organized by discharge month. We use the term patient to refer to a discrete admission; an individual patient may be included in the database more than once.
To avoid any possible issues regarding the use of protected health information in the analyses, dates of admission and discharge were reported by month and year; day-of-service detail was provided using chronological days; and the age of patients older than 89 years were assigned an age of 89 years. The Saint Louis University Institutional Review Board approved the study and waived the requirement for patient informed consent.
Data were obtained from several periods to allow for examination of changes in prescribing patterns following the release of the 2 sentinel articles challenging the safety of nesiritide (March 29 and April 20, 2005) . The specific periods were selected to allow for before-and-after publication comparisons and a reference point before nesiritide was introduced. Specifically, we examined the period January to April 2005, which includes the 4 months just prior to the publication of the mortality article 28 and the subsequent 8 months in the same calendar year (May-December). To compare on a yearover-year basis, we divided the previous year into the same periods (JanuaryApril 2004 and May-December 2004). In addition, we obtained data for the time frame of January to August 2001, representing the period prior to the approval and introduction of nesiritide to the market (September 2001) to examine secular trends in the utilization of vasoactive therapies. The number of hospitals (n=491) varied slightly over time, contributing to differences in the number of patients during each period.
Variables in the PREMIER database include patient demographic information (eg, age, sex, and race based on UB92 coding), admission and discharge dates by month and year, concurrent background heart failure therapy (ACE inhibitor, angiotensin-receptor antagonist, ␤ adrenergic antagonist, digoxin, diuretic, aldosterone antagonist), type of admission, length of stay (including days in intensive care), intravenous drug used (including day of initiation and discontinuation of therapy), patient discharge status, primary and secondary International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes (limited to 1 secondary code in the 2001 sample), hospital characteristics (size, geographic location, and teaching status), payer type, and the specialty of both the admitting and attending physician.
Inclusion criteria included (1) a primary ICD-9 diagnosis of heart failure (a detailed list is available on request), (2) if either the admitting or attending physician was coded as a cardiologist. Secondary analyses were performed in which all admissions with a secondary ICD-9 code for heart failure were considered. Additionally, we were in- Table 1 We used logistic regression to identify characteristics associated with physician use of nesiritide among patients with heart failure. The following characteristics were included: age (19-64, 65-74, 75-84, Ն85), race (black, other), sex, use of background heart failure medications as defined above, hospital location (urban or rural) and geographical region, hospital teaching status, hospital size (defined by 0-100, 101-400, 401-600, Ͼ601 beds), physician (cardiologist, other), and payer type. Odds ratios (ORs) were calculated to evaluate risk. Time interaction variables for before and after publication of the survival article were used to evaluate risks based on patient and hospital characteristics for both periods, as well as change in risk between periods. Data management and analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary, NC). Differences were considered statistically significant at a 2-sided PϽ.05 level.
RESULTS

Baseline Characteristics and Demographics
The total number of hospitalizations across all periods with a primary ICD-9 diagnosis code for heart failure was 385 627. Patients were predominantly women, white, and elderly (mean [SD] 001; FIGURE 2) .
Furthermore, a separate analysis was limited to data supplied by hospitals that contributed patient information throughout all 4 periods in 2004 and 
Timing of Administration of Nesiritide
Comparison of mean values between January-April and May-December 2005 revealed a mean (SD) decrease in length of stay from 8.0 (7.9) to 7.6 (7.4) days, respectively (PϽ.005), and length of therapy from 2.3 (1.7) to 2.1 (1.4) days, respectively (PϽ.001). The day of initiation changed minimally from 1.9 (2.2) to 2.0 (2.5) days, respectively (PϽ.002).
Predictors of Nesiritide Use
Decreases in nesiritide use were found in all subgroups analyzed (TABLE 2) . In a logistic regression analysis, a number of factors, including younger patient age, nonblack race, male sex, hospital location outside the Northeast region, care by a cardiologist, and background use of heart failure medications predicted use of nesiritide up to April 2005. Following the publication of the mortality article, the odds ratio for use among elderly patients (age Ն85 years) relative to a reference group (19-64 years) declined in a statistically significant manner, possibly reflecting heightened concerns about the potential risks of nesiritide in this population. Similar findings were observed for urban and nonteaching hospitals and the Northeast region. The leading primary ICD-9 diagnoses among the 23 823 nesiritide users were acute myocardial infarction (25.6%, n = 6104), respiratory illness or failure (19.5%, n = 4645), and coronary atherosclerosis (7.8%, n=1866). We observed a significant decrease in nesiritide use that was similar to the decrease in the primary cohort.
Use of Nesiritide Among Patients Without an ICD-9 Heart Failure Code
A total of 3190 patients during the January 2004-December 2005 period received nesiritide without a primary or secondary diagnosis of heart failure (4.96% of all nesiritide use). A more conservative estimate that removes all patients with cardiovascular codes (with the exception of nonspecific chest pain, conduction disorders, cardiac dysrhythmias, and essential hypertension) yielded 569 patients (0.88%).
COMMENT
The adoption of new cardiovascular medications and the influences on physician decision making that affect prescribing practice have been extensively studied. Prescribing practices vary by provider characteristics and can be affected by a wide range of factors. [40] [41] [42] [43] For the condition of congestive heart failure, available data suggest that some medications, such as ACE inhibitors, were underused after publication of definitive randomized placebo-controlled clinical trials that demonstrated a survival benefit. 7 Other medications, such as aldactone, may have been rapidly adopted albeit in inappropriate populations. 4, 16 However, most of the focus has been on the adoption rather than its opposite, when safety or efficacy of an established drug is brought into question.
Recently, several analyses were published that suggested the existence of a safety concern with the intravenous drug nesiritide, approved by the US Food and Drug Administration for the treatment of symptomatic, acutely decompensated heart failure. Using data from a representative cohort of patients with heart failure admitted to acute care hospitals in the United States during the periods immediately before and after the publication dates, we observed a highly significant decrease in the use of the drug. The decrease occurred in all subgroups. Use among elderly patients was initially lower than in other age groups and declined at a more rapid rate. At the same time, for those patients receiving nesiritide, the duration of therapy decreased and the Abbreviations: ACE: angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ␤-blocker: ␤-blocker approved for heart failure; CI, confidence interval; OR, odds ratio. *All reference groups for concurrent therapies are those individuals not receiving the specific drug. †Including the Veterans Health Administration, Tricare, and Indian Health Services.
time from admission to administration increased slightly. These findings suggest that physicians may respond rapidly in the face of highly publicized negative postapproval data, perhaps at a greater speed and to a greater extent than when positive efficacy data for a new medication are published. Furthermore, we found that there were downstream consequences. For example, there was a lack of compensatory uptake of alternative intravenous vasoactive therapies, although inotrope use became more likely among patients offered this treatment option. The overall percentage of patients receiving nondiuretic intravenous therapy, which increased dramatically after nesiritide approval, has fallen to levels below those observed prior to nesiritide approval. Hence, the publication of articles that call into question safety (and potentially efficacy) of approved medications may have important and early effects on patient care.
Prior studies have shown that the use of cardiovascular drugs may also decrease in the absence of major new findings. In the cases of digoxin for congestive heart failure and lidocaine for routine administration following suspected acute myocardial infarction, changes in use appear to be related to background secular trends 17, 19 rather than to a particular publication or highly publicized new clinical findings. Indeed, when safety concerns have been described, the medication in question has often been removed from the market as in the cases of rofecoxib, mibefradil, and short-acting nifedipine. However, the way in which postmarketing data can affect practice remains an important area for investigation. 44 In addition, in our study, off-label administration of nesiritide appears to have comprised a small proportion of overall use. With a conservative assumption, namely that any primary or secondary ICD-9 code for heart failure reflects on-label use, an estimate of approximately 5% was derived.
Further study is required to assess the degree to which current trends with nesiritide will continue and the long-term impact on the pharmacological treatment of patients with decompensated heart failure. Newer trial data and alternative drug therapies may influence practice and modify current approaches; nevertheless, the reassessment of nesiritide has had pronounced and rapid effects on practitioners, patients, and-by extension-industry. 39 
Limitations
It is possible that the change in nesiritide prescribing reflects a wide array of influences including the mass media and changes in marketing. 45 A definitive causal relationship with any single factor cannot be made. However, the fact that a continual decrease was seen over a period of 10 months suggests, from an analytical perspective, that the publications 27,28 had a pronounced influence on practice.
Additionally, we do not know details about antecedent care or prior use of intravenous vasoactive therapy in this patient cohort. The reasons for the admission (eg, noncompliance, new arrhythmia, etc) are not known. Furthermore, it is possible that a given patient may be admitted more than once during the period under study and therefore contributes to the database with each admission. We did not specifically look at dosing of intravenous therapy, because most doses are based on patient weight and may be frequently changed during the course of the hospitalization. However, it is possible that the average perkilogram dose of nesiritide declined during the period under study and this would likely represent an important shift toward on-label use, for which a dose of 0.01 µg/kg per minute is standard.
We were unable to pinpoint the exact timing of the beginning of the decrease in nesiritide use, because the article suggesting a detrimental effect on mortality was published on the 20th day of the month (April 2005). Our data provides month and year of admission (as well as day of service detail) but does not include the precise calendar date. Nevertheless, the impact, if sudden, would have been limited to the last 10 days of the month. Furthermore, since the database is driven by month of discharge, the data we have for December 2005 does not include all hospitalizations in that month. Patients admitted in December 2005 and discharged in January 2006, are not captured in the database. Because these patients may have longer lengths of stay and hence be considered sicker and more likely to receive intravenous vasoactive therapy, we may have slightly underestimated the use of nesiritide in that month. Finally, we may have underestimated the participation of a cardiologist in the care of the patients because we were limited to the admitting physician of record and the attending physician during the hospitalization.
Conclusions
In conclusion, we have observed a rapid de-adoption of a drug prescribed for decompensated heart failure after a series of publications brought into question its clinical safety profile. Because intravenous vasoactive therapy use was increasingly driven by nesiritide, the overall use of these therapies also declined. However, among patients on intravenous vasoactive therapy, a higher proportion was prescribed intravenous inotropic drugs. The rate of deadoption appears to be faster than what has been conventionally described for the adoption of new heart failure medications. Whether the magnitude of these changes can be anticipated or are reproducible in other therapeutic areas remains to be seen.
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